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Background: Hearing loss in children born before 32 weeks of gestation is more prevalent than in full term infants.
Aminoglycoside antibiotics are routinely used to treat bacterial infections in babies on neonatal intensive care units.
However, this type of medication can have harmful effects on the auditory system. In order to avoid this blood
levels should be maintained in the therapeutic range. However in individuals with a mitochondrial genetic variant
(m.1555A > G), permanent hearing loss can occur even when drug levels are within normal limits. The aim of the
study is to investigate the burden that the m.1555A > G mutation represents to deafness in very preterm infants.
Method: This is a case control study of children born at less than 32 completed weeks of gestation with confirmed
hearing loss. Children in the control group will be matched for sex, gestational age and neonatal intensive care unit
on which they were treated, and will have normal hearing. Saliva samples will be taken from children in both
groups; DNA will be extracted and tested for the mutation. Retrospective pharmacological data and clinical history
will be abstracted from the medical notes. Risk associated with gentamicin, m.1555A > G and other co-morbid risk
factors will be evaluated using conditional logistic regression.
Discussion: If there is an increased burden of hearing loss with m.1555A > G and aminoglycoside use,
consideration will be given to genetic testing during pregnancy, postnatal testing prior to drug administration, or
the use of an alternative first line antibiotic. Detailed perinatal data collection will also allow greater definition of
the causal pathway of acquired hearing loss in very preterm children.
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Advances in neonatal intensive care have resulted in
substantial improvements in outcome, in particular the
survival of very preterm infants [1]. However, among the
surviving population there is a high level of disability
[2,3]. The prevalence of deafness is around 1-2% in pre-
term or low birth weight babies, and is often co-morbid
with other disabilities such as cerebral palsy, and intel-
lectual and visual impairment [4]. Hearing loss in this
group of infants is up to ten times more prevalent than
in term babies [4]. Deafness has long term implications
for communication skills, educational achievement, and
overall quality of life, even in mild cases of unilateral
and bilateral hearing loss [5]. The cause of acquired* Correspondence: maria.bitner@ucl.ac.uk
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article, unless otherwise stated.deafness in this group is likely to be multifactorial al-
though several high risk factors have been suggested.
These include very low birth weight, severe jaundice [6],
hypoxia, medication [7] and infection [8].
Infection is a common occurrence during the neonatal
period due to the underdeveloped immune system of the
preterm infant, and can rapidly become life threatening.
Aminoglycoside antibiotics are frequently used as a first
line of treatment for suspected or proven bacterial sep-
sis. High efficacy, low levels of resistance and low cost
make this group of medications an effective and recom-
mended option [9]. Aminoglycoside exposure is known
to have nephrotoxic and ototoxic side effects, hence
regular monitoring of blood concentrations. However
reassurance has been taken from the repeated observa-
tions that aminoglycoside toxicity does not appear to be
a frequent occurrence in this population.
A genetic predisposition renders some individuals more
susceptible to rapidly progressive, permanent hearing lossCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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the therapeutic range. The most common predisposing
mutation is the mitochondrial m.1555A >G variant, a ma-
ternally inherited genetic trait. Although the exact process
of aminoglycoside induced deafness is unknown it is
thought that the m.1555A >G mutation enables aminogly-
cosides to bind to the mitochondrial ribosomes more
readily than the normal genetic sequence. This is thought
to result in abnormal translation of mitochondrial proteins
necessary for energy production. Hair cells in the inner
ear are metabolically highly active and consequently have
large numbers of mitochondria. In addition, aminoglyco-
sides easily enter the hair cells but take a long time to be
cleared [10].
In susceptible individuals, a single dose of aminoglyco-
side may cause hearing loss. Early indications were that
penetrance of deafness following aminoglycoside expos-
ure was close to 100% in the presence of m.1555A > G.
For example, in a study of European families with a his-
tory of maternally transmitted deafness and presence of
the m.1555A > G mutation, all individuals who received
aminoglycosides became deaf [11]. Furthermore, there
was a lower mean age of onset of deafness in the group
exposed to these antibiotics implicating aminoglycosides
as a catalyst for rapidly progressive hearing loss. How-
ever, it is possible that such research is biased. Individ-
uals that are given aminoglycosides with no ill effect are
unlikely to be genetically screened for the mutation.
More recently in identical twins born at 24 weeks gesta-
tion both with m.1555A > G and treated with aminogly-
cosides, only one of the twins has hearing loss. The deaf
twin received multiple courses of aminoglycosides whilst
the twin with normal hearing received a single course
(unpublished data). The hearing twin showed no clinical
indication for genetic screening, but was tested with the
other twin. It is possible that single courses may be tol-
erated in some cases.
The Avon Longitudinal Study of Parents and Children
cohort (ALSPAC) showed the prevalence of the mutation
to be 1 in 520 children [12]. Audiological screening was
normal at the age of 9 years, there were no histories of ad-
missions to neonatal units and exposure to aminoglyco-
sides was thought to be unlikely. Thus, there were no
clinically distinguishing features between those with the
mutation and those without, and therefore no reason
under normal circumstances for genetic testing. Neverthe-
less, it is also possible that there had been exposure to oto-
toxic medication but hearing had been preserved, which
would indicate that the penetrance of aminoglycoside-
mediated ototoxicity in m.1555A >G is less than previous
research has suggested. These findings demonstrate the
need for further research in this domain.
The primary aim of this study is to evaluate the contri-
bution of the m.1555A >G mutation to acquired deafnessin babies born at a gestational age of less than 32 weeks,
who are likely to have received multiple doses of amino-
glycoside antibiotics. Further to this, the study aims to cal-
culate the relative odds of carrying the genetic variant and
being in the deaf group versus the hearing group. Risk
associated with gentamicin, m.1555A >G and other co-
morbid risk factors will be evaluated using conditional lo-
gistic regression to determine potential gene-drug interac-
tions in the context of other ototoxic risks.
Method/Design
Study design
Case control study, with 5 controls for each index case.
Definition of index cases
Any child born at 31 weeks and 6 days gestation or less
with confirmed hearing loss (>40dBHL). Children with
clear genetic syndromic causes for hearing loss will be
excluded.
Index population
This will include all children with hearing loss who were
born at less than 31 weeks and 6 days gestation between
January 2009 and December 2013. All children will have
been treated in a Neonatal Intensive Care Unit (NICU)
within the Greater London region. Participants will be
identified through electronic databases, hearing assess-
ment centres, neonatal follow up services and advertise-
ments promoting the study.
Control population
Each child recruited with hearing loss will be matched
with five children with normal hearing. Control children
will be identified through the Standardised Electronic
Neonatal Database (SEND) which contains demographic
and clinical information about infants admitted to neo-
natal units across London. Matching will be based upon
gestational age (same number of completed weeks of ges-
tation), sex (male/female) and neonatal unit on which they
received their neonatal intensive care over the first two
weeks after birth. Control children with partially complete
or missing pharmacological records will be excluded on
the premise that other matched control children will be
identifiable with more comprehensive records.
Procedure
Index children will be invited to participate in the study
via a letter sent by the audiological paediatrician respon-
sible for their care. This will enclose information about
the study and parents who require further information or
would like to participate will be asked to return a short
form to indicate their willingness to speak to the research
team. The research nurse will telephone the parent(s), ex-
plain the study further and arrange a convenient time to
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tify themselves to the research team via newsletters or ad-
vertisements will be spoken to directly by the research
team. Written informed consent will be obtained for gen-
etic testing of a saliva sample, and to extract data from
neonatal and audiological clinical notes. During a subse-
quent home visit saliva samples will be taken if testing for
m.1555A >G has not been undertaken as part of clinical
care. Saliva samples will be collected using an Oragene
collection kit and transported to the laboratory for testing.
DNA is extracted using standard procedures and analysed
by polymerase chain reaction and restriction enzyme
digestion, followed by sequence confirmation by bi-
directional Sanger sequencing in mutation-positive cases.
Matched controls will be identified though the na-
tional neonatal research dataset. Parents of control chil-
dren identified will be invited to participate by letter
sent by the clinician responsible for their neonatal care.
Those wishing to participate in the study will contact
the research team as above.
Children identified to have the mutation will be
recalled and the presence of m.1555A > G reconfirmed
by analysis of DNA extracted from a second sample.
Families confirmed to have the mutation will be offered
genetic counselling. Since mitochondrial DNA is mater-
nally inherited, there are additional implications for ex-
tended maternal family members, who will also be
offered genetic counselling.
Clinical data will be extracted from the neonatal and
audiological medical notes for all children using an agreed
proforma to record details of demographics, clinical events
and therapeutic history, with serum levels of drugs as
available. Data will be collected by day after birth to iden-
tify coincidence of risk factors. Pharmacy records will be
examined to confirm aminoglycoside exposure, including
dose, duration, number of courses and blood level concen-
trations. Audiological records will be reviewed to define
the severity and pattern of hearing loss.
Data will be encoded for data analysis using double entry
into an automated error detection system in SPSS (IBM
Inc) in its latest version. Subsequently data will be checked
for outliers, prior to analysis using Stata (Version 13).
Sample size
The annual birth-rate in London is approximately 120
000, (600 000 in 5 years). It is estimated that 1% of these
babies have a birth weight of less than 1501 g [13]. This
gives a likely population of babies at less than 32 weeks
gestational age of 3 000–6 000 over 5 years. The preva-
lence of hearing loss within this group is 1-2% [4], pre-
dicting 30–120 children with hearing loss over the
5 year study period. From a cohort of 3 000–6 000 chil-
dren, we anticipate that 6–12 children will have the
m.1555A > G mutation, given a mutation frequency of 1in 526 (95% CI 1 in 357 to 1 in 770) [14]. For each index
child, we will recruit up to 5 matched controls.
Thus the total study population should include be-
tween 180–720 children, 30–120 index and 150–600
controls.
Statistical analysis
The burden of disease will be calculated as the propor-
tion (and 95% CI) of children with hearing loss that have
the mutation, using the method of Wilson. The odds ra-
tio of children with the m.1555A > G mutation having
hearing loss will be calculated using Fisher’s exact test.
The analysis for the burden of disease and the relative
risk of deafness for those with the mutation will initially
include all cases. This will be repeated excluding chil-
dren who received less than one dose of aminoglycoside
medication, and repeated again excluding those who re-
ceived fewer than two doses.
The antecedents and associates of hearing loss will be
determined using conditional logistic regression to ac-
count for matching. Factors will be evaluated individu-
ally and as combinations occurring simultaneously to
account for additive risk.
Ethical issues
The study has been approved by the National Research
Ethics Service (NRES Committee London – Central, ref:
12/LO/0005) and is registered under the National Insti-
tute for Health Research (NIHR) Portfolio scheme. The
study is funded by a financial grant from Action on
Hearing Loss; the funding source has had no input into
the design or execution of the research study.
Discussion
We aim to investigate the contribution of m.1555A > G
to deafness in preterm infants where aminoglycosides
are likely to have been used and to evaluate this role
within the occurrence of multiple risk factors for hearing
loss identified during neonatal intensive care. We hy-
pothesise that the mutation will make a significant con-
tribution to deafness even when aminoglycoside levels
are maintained within the therapeutic range. From our
clinical experience, we suspect that in some cases, single
courses of aminoglycosides may be tolerated but mul-
tiple courses may not be, possibly due to the accumula-
tion of the medication in the hair cells of the inner ear,
which can take several months to clear. Multiple courses
of aminoglycosides during the neonatal period would
thus inhibit the clearance process.
Alongside such a potential interaction, to date multiple
studies have failed to provide consistent evidence for
specific risk factors. Intriguingly one small study has re-
ported that it is the coincidence of risk factors that may
determine the development of hearing loss [4]. A range
Bitner-Glindzicz et al. BMC Pediatrics 2014, 14:66 Page 4 of 4
http://www.biomedcentral.com/1471-2431/14/66of factors, such as other ototoxic drugs, hyperbilirubi-
naemia, acidosis and sepsis, will be evaluated as part of
this study and these risks assessed for co-occurrence.
The conditional case control analysis will maximise the
potential sensitivity of this large study to determine the
presence of such associations.
Should m.1555A > G be implicated in the aetiology of
neonatal hearing loss in very preterm babies, then alter-
native strategies may be necessary to manage preterm
neonatal sepsis in affected babies.
Alternative first line antibiotics could be used instead
of aminoglycosides. Using more broad spectrum agents
runs the risk of increasing patterns of bacterial resist-
ance in the relatively closed microbiological setting of
neonatal intensive care. Further, owing to low cost and
the synergistic effects of aminoglycosides, their use is
preferred by many services for babies at risk of life
threatening infection, considering that the risk of amino-
glycoside associated hearing loss is as yet unsubstanti-
ated in newborn babies.
A further alternative would be universal genetic screen-
ing (of pregnant women) or focussed genetic screening of
babies prior to treatment, which is at present impracticable
[15]. Due to the nature of illness experienced by many ba-
bies being treated on the neonatal intensive care unit, ami-
noglycoside administration may be required before the
results of genetic screening are available. Screening women
during pregnancy would overcome this since the mutation
is maternally inherited but this is expensive and would re-
quire clear evidence that this interaction is a key step in
the causal pathway. This would, however, enable early rec-
ognition of the potential for hearing impairment and lead
to the use of an alternative medication for these infants.
Mitogent is designed to provide critical answers con-
cerning the aetiology of acquired hearing impairment in
very preterm babies and specifically to identify the role of
aminoglycoside toxicity in individuals with m.1555A >G.
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